
Journal of Medicinal Chemistry p. 1273 - 1279 (1992)
Update date:2022-08-04
Topics:
Lawrence
Venepalli
Appell
Goswami
Logan
Tomczuk
Yanni
The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro- 1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.
View MoreContact:18669908765
Address:Zibo City, Shandong Province, P.R.China
Shanghai Taibao Pharmaceutical Technology Co., Ltd(expird)
Contact:021-52217366
Address:shanghai
Contact:0086-357-6662688
Address:Zhaocheng town, Hongtong County, Linfen City, Shanxi Province
Shanghai Sharing technologies Co., Ltd.
Contact:86-021-66787223
Address:No11, Lane 225, Jinxiang Road,Pudong district
Longhui qunfeng Chemical Co., Ltd
Contact:86-731-82173407
Address:South-east Industrial Park, Longhui County, Hunan Province, China
Doi:10.3906/kim-1110-43
(2012)Doi:10.1002/ejoc.201200158
(2012)Doi:10.1016/j.jorganchem.2012.05.023
(2012)Doi:10.1039/C5RA27624A
(2016)Doi:10.1021/jacs.0c02721
(2020)Doi:10.3109/14756366.2011.597748
(2012)